سعر اينوكسيرت 0.5 جم فيال عضل 2022

Enoxirt (ceftriaxone) 0.5 gm vial for i.m. injection, Julphar.

• Treatment of infections caused by susceptible bacteria, including lower respiratory tract infections, acute bacterial otitis media, skin and skin-structure infections, urinary tract infections, uncomplicated gonorrhoea, pelvic inflammatory disease, bacterial septicaemia, bone and joint infections, intra-abdominal infections and meningitis; also surgical prophylaxis (US label).Population: Adults and paediatric patientsDailyMed / FDA

• Reported reactions include local reactions (pain, induration, phlebitis), rash, eosinophilia, thrombocytosis, leukopenia and diarrhoea (US label).International label, same formulation · DailyMed / FDA

• Known hypersensitivity to ceftriaxone, any excipient or any other cephalosporin (US label).International label, same formulation · DailyMed / FDA
• Premature neonates up to a postmenstrual age of 41 weeks, and hyperbilirubinaemic neonates (risk of bilirubin encephalopathy) (US label).International label, same formulation · DailyMed / FDA
• Neonates (≤28 days) who require or are expected to require calcium-containing IV solutions, because of ceftriaxone-calcium precipitation (US label).International label, same formulation · DailyMed / FDA

• Serious hypersensitivity reactions including anaphylaxis; ask about previous reactions to cephalosporins, penicillins and other beta-lactams (US label).International label, same formulation · DailyMed / FDA
• Serious neurological adverse reactions (encephalopathy, seizures, myoclonus, non-convulsive status epilepticus), some in severe renal impairment without dose adjustment (US label).International label, same formulation · DailyMed / FDA
• Immune-mediated haemolytic anaemia, including fatal cases, has been reported (US label).International label, same formulation · DailyMed / FDA

• Calcium-containing IV solutionsDo not mix or co-administer with calcium-containing IV solutions in neonates; fatal ceftriaxone-calcium precipitates in lungs and kidneys reported in neonates (US label).DailyMed / FDA

• Animal studies showed no embryotoxicity, fetotoxicity or teratogenicity, but there are no adequate and well-controlled studies in pregnant women; use only if clearly needed (US label, older format).International label, same formulation · DailyMed / FDA
• Low concentrations are excreted in human milk; use with caution in nursing women (US label).International label, same formulation · DailyMed / FDA

• Ceftriaxone: Long-acting third-generation cephalosporin inhibiting cell-wall synthesis via PBP binding; once-daily dosing common.